Welcome to our dedicated page for AIM ImmunoTech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) is a pioneering immuno-pharma company based in Ocala, Florida, focused on the research and development of innovative therapeutics aimed at treating a variety of cancers, immune disorders, and viral diseases including COVID-19. The company's flagship product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a highly selective TLR3 agonist immuno-modulator with broad-spectrum activity. Ampligen is currently undergoing extensive clinical trials targeting globally important cancers and viral diseases.
AIM ImmunoTech's product portfolio also includes Alferon N Injection, an injectable formulation of natural alpha interferon used to treat a specific category of genital warts, a sexually transmitted disease. Ampligen has shown promising results in the treatment of chronic fatigue syndrome and is being developed for other indications like hepatitis B, HIV, and several cancer types, including renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, urothelial cancer, prostate cancer, and pancreatic cancer.
In recent developments, AIM ImmunoTech announced positive top-line interim data indicating that the combination of Ampligen with Keytruda (pembrolizumab) could be significantly more effective than pembrolizumab alone in treating recurrent ovarian cancer. The company is also working on various clinical trials, including studies for treating post-COVID conditions and long COVID, led by renowned medical experts like Dr. Charles Lapp.
AIM ImmunoTech has formed strategic research agreements with prominent institutions such as the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., exploring the potential of Ampligen as an adjuvant therapy for COVID-19. The company continues to focus on operational execution and has successfully completed cGMP manufacturing of over 9,000 clinical vials of Ampligen, which is crucial for its ongoing and upcoming clinical trials.
The company's leadership team, headed by CEO Thomas K. Equels, is committed to advancing its pipeline and achieving clinical and commercial success. AIM ImmunoTech engages with its stakeholders through regular updates and CEO Corner segments, providing insights into its clinical programs and financial performance, ensuring transparency and fostering investor confidence.
For more detailed information, visit the official website and connect with AIM ImmunoTech on social media platforms such as X, LinkedIn, and Facebook.
AIM ImmunoTech Inc. (NYSE: AIM) reported its Q2 2022 financial results, revealing a cash position of $34.5 million, up from $32.1 million at the end of 2021. Positive developments include upcoming Phase 2 studies for Ampligen in pancreatic cancer and favorable data from trials targeting advanced ovarian and colorectal cancers. The company anticipates reaching key clinical and regulatory milestones and expects to maintain sufficient capital through 2023. Despite industry challenges, AIM remains focused on advancing Ampligen's therapeutic potential.
AIM ImmunoTech Inc. (AIM) announced positive preliminary data from its Expanded Access Program for Ampligen, an investigational drug for treating Post-COVID conditions. The results indicated significant improvements in chronic fatigue among patients receiving Ampligen. Based on these findings, AIM plans to file an Investigational New Drug (IND) application with the FDA for a Phase 2 study of Ampligen targeting long COVID. The drug is being developed for various conditions, including cancers and immune disorders.
AIM ImmunoTech reported promising results for Ampligen® (rintatolimod) in treating metastatic and locally advanced pancreatic cancer. Data presented by Professor C.H.J. van Eijck at the 5th Dutch Multidisciplinary Gastrointestinal Oncology Congress indicated improved survival rates for patients undergoing this maintenance therapy post-chemotherapy with FOLFIRINOX. The company plans to advance Ampligen into a Phase 2 clinical study (AMP-270) aimed at evaluating its efficacy in patients with locally advanced pancreatic cancer, enrolling around 90 subjects across the U.S. and Europe.
AIM ImmunoTech Inc. has filed a complaint in federal court against an activist group led by Jonathan Jorgl, seeking to prevent a potential hostile takeover and address violations of securities laws. The AIM Board unanimously rejected Jorgl's nomination notice due to significant deficiencies, including false statements. AIM emphasizes its commitment to protecting stockholders and achieving financial stability, with ~$44.5 million in liquid assets and ongoing oncology clinical trials showing promising interim results. AIM reassures stockholders that no immediate action is required.
AIM ImmunoTech will host a live video webcast on July 25, 2022, at 8:30 AM ET, featuring a moderated roundtable with key opinion leader Professor C.H.J. van Eijck from Erasmus Medical Center.
The event will cover the company's lead asset, Ampligen (rintatolimod), focusing on its clinical development for pancreatic cancer.
Investors can submit questions during the session. A recording will be available on the company’s website after the event.
AIM ImmunoTech Inc. has signed a lease for a 5,210 square foot R&D facility at the New Jersey Bioscience Center, a leading incubator focused on life sciences. This move aims to enhance the research and development of Ampligen, their lead product targeting cancers and viral diseases, including COVID-19. The New Jersey Economic Development Authority supports the initiative, underlining AIM's commitment to advancing therapeutics. The NJBC has invested over $70 million into its facilities to support life science innovations.
AIM ImmunoTech Inc. announced the issuance of Patent No. 2027383 by the Netherlands Patent Office, covering Ampligen (rintatolimod) and related products for treating COVID-19, with patent protection extending until 2041. The patent supports AIM’s ongoing research programs in the Netherlands to combat various cancers, immune disorders, and viral diseases. The company has filed multiple patent applications covering Ampligen, enhanced immunity against COVID-19 variants, and is progressing towards filing an IND application for a Phase 2 study addressing Long COVID conditions.
AIM ImmunoTech Inc. (NYSE: AIM) announced that CEO Thomas K. Equels will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, FL, and virtually. The company focuses on developing therapeutics for cancer, immune disorders, and viral diseases, including COVID-19. A video webcast of the presentation will be available on-demand starting May 24, 2022. AIM's lead product, Ampligen®, is in clinical trials for various cancers and is approved for treatment of ME/CFS in Argentina.
AIM ImmunoTech Inc. (NYSE: AIM) announced progress in its research on Ampligen, aimed at treating Long COVID and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). A Phase 3 trial indicated a 51.2% positive response in patients with early ME/CFS symptoms. Following promising results from an expanded access program, AIM plans to file an Investigational New Drug application for a Phase 2 study of Ampligen. Experts express optimism about Ampligen's potential benefits for Long COVID patients, highlighting the urgency for effective therapeutics.
AIM ImmunoTech Inc. (NYSE: AIM) reported significant clinical advancements in the first quarter of 2022, showcasing Ampligen's efficacy in late-stage pancreatic cancer, ovarian cancer, and triple-negative breast cancer. The company is on track to begin a Phase 2 study for Ampligen in pancreatic cancer by Q3 2022. AIM also holds a robust cash position of $44.5 million, expected to support operations through 2023. The FDA has lifted the clinical hold on its IND application, allowing further studies to proceed.
FAQ
What is the current stock price of AIM ImmunoTech (AIM)?
What is the market cap of AIM ImmunoTech (AIM)?
What is AIM ImmunoTech's main focus?
What are AIM ImmunoTech's key products?
What recent achievements has AIM ImmunoTech made?
Who are AIM ImmunoTech's notable partners?
What clinical trials is AIM ImmunoTech currently conducting?
How can investors access AIM ImmunoTech's financial reports?
How does AIM ImmunoTech engage with its stakeholders?
What is the significance of Ampligen in AIM ImmunoTech's portfolio?
Who leads AIM ImmunoTech?
Where can more information about AIM ImmunoTech be found?
